↓ Skip to main content

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Overview of attention for article published in Blood, February 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet
blogs
2 blogs
twitter
13 X users
patent
10 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
615 Dimensions

Readers on

mendeley
420 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Published in
Blood, February 2016
DOI 10.1182/blood-2015-08-665547
Pubmed ID
Authors

Rebecca Gardner, David Wu, Sindhu Cherian, Min Fang, Laïla-Aïcha Hanafi, Olivia Finney, Hannah Smithers, Michael C Jensen, Stanley R Riddell, David G Maloney, Cameron J Turtle

Abstract

Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)-modified T cells is a remarkably effective approach to treat patients with relapsed and refractory CD19(+) B cell malignancies. We treated 7 patients with B-cell acute lymphoblastic leukemia (B-ALL) harboring rearrangement of the mixed lineage leukemia (MLL) gene with CD19 CAR-T cells. All patients achieved complete remission in the bone marrow by flow cytometry after CD19 CAR-T cell therapy; however, within one month of CAR-T cell infusion two of the patients developed acute myeloid leukemia that was clonally related to their B-ALL, a novel mechanism of CD19-negative immune escape. These reports have implications for the management of patients with relapsed and refractory MLL-B-ALL who receive CD19 CAR-T cell therapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 420 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Portugal 1 <1%
Belgium 1 <1%
Unknown 417 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 77 18%
Researcher 61 15%
Student > Master 40 10%
Student > Bachelor 39 9%
Student > Doctoral Student 29 7%
Other 58 14%
Unknown 116 28%
Readers by discipline Count As %
Medicine and Dentistry 103 25%
Biochemistry, Genetics and Molecular Biology 72 17%
Immunology and Microbiology 49 12%
Agricultural and Biological Sciences 40 10%
Pharmacology, Toxicology and Pharmaceutical Science 8 2%
Other 26 6%
Unknown 122 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 39. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2024.
All research outputs
#1,044,266
of 25,371,288 outputs
Outputs from Blood
#759
of 33,239 outputs
Outputs of similar age
#17,655
of 313,044 outputs
Outputs of similar age from Blood
#21
of 275 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,239 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,044 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 275 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.